Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Be Catching Up With FDAAA Workload, Latest Performance Data Suggests

Executive Summary

Preliminary FDA data indicate the agency may be catching up with the workload imposed by the FDA Amendments Act, with the agency reporting it could meet 10 of 12 review performance goals for NDAs and BLAs submitted in fiscal 2009.

You may also be interested in...



Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13

Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.

Related Content

Topics

UsernamePublicRestriction

Register

PS052750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel